Search

Eben P Tessari

from Boston, MA
Age ~43
Get Report
Also known as:
Eben M Tessari
Phone and address:
225 Dorchester St UNIT 9, Boston, MA 02127
(617) 803-3729
Related to:
Courtney E Goudreau, 43
Connected to:
Paul E Tessari, 60Trisha N Tessari, 63Brittney N Tessaro, 39Carissa E Tessaro, 40Jerry L Tessarolo, 69Jessie D Tessaro, 67Louise T Tessaro, 88Trudy D Tessaro, 60Linda G Tessarvich, 64Eric J Tessein, 33

Eben Tessari Phones & Addresses

  • 225 Dorchester St UNIT 9, South Boston, MA 02127 (617) 803-3729
  • Boston, MA
  • Rangeley, ME
  • 25 Karen Dr, Gardiner, ME 04345 (207) 582-2549
  • Quincy, MA
  • Hanover, MA
  • Cambridge, MA
  • 10 Speare Pl, Boston, MA 02115

Work

Company: Series c private placement Sep 2014 Position: Licensed pre-clinical compounds to vc

Education

School / High School: Suffolk University 2009 Specialities: MBA in finance and IP law

Skills

Strategy • Lifesciences • Pharmaceutical Industry • Strategic Planning • Analytics • Biotechnology • Clinical Development • Competitive Intelligence • Life Sciences • Business Development • Financial Modeling • Forecasting • Valuation • Mergers and Acquisitions • Clinical Trials • Drug Development • Technology Transfer • Drug Discovery • Licensing • Oncology • Biopharmaceuticals • Dcf • Sensitivity • Monte Carlo Simulation • Vba • Market Research • Due Diligence • Infectious Diseases • Fda • Analysis

Interests

Economic Empowerment • Civil Rights and Social Action • Education • Science and Technology • Health

Industries

Biotechnology

Resumes

Resumes

Eben Tessari Photo 1

Chief Business Officer

View page
Location:
154 west 2Nd St, Boston, MA 02127
Industry:
Biotechnology
Work:
Zalicus Incorporated since Mar 2013
Associate Director Business Development
Vertex Pharmaceuticals - Cambridge, MA Apr 2010 - Mar 2013
Senior Manager - New Product Strategy & Decision Analytics
Codon Partners - Cambridge, MA May 2009 - Jun 2010
Consultant
EPIX Pharmaceuticals Nov 2007 - Mar 2009
Business Development Associate
Millennium Pharmaceuticals 2005 - 2006
Research Associate
Education:
Suffolk University Law School 2009 - 2014
JD, Intellectual Property Law Suffolk University - Sawyer School of Management 2009 - 2012
MBA, Banking, Corporate, Finance, and Securities Law Boston University 2005 - 2007
MS, Biomedical Engineering Northeastern University 2000 - 2004
BS, Neuroscience
Skills:
Strategy
Lifesciences
Pharmaceutical Industry
Strategic Planning
Analytics
Biotechnology
Clinical Development
Competitive Intelligence
Life Sciences
Business Development
Financial Modeling
Forecasting
Valuation
Mergers and Acquisitions
Clinical Trials
Drug Development
Technology Transfer
Drug Discovery
Licensing
Oncology
Biopharmaceuticals
Dcf
Sensitivity
Monte Carlo Simulation
Vba
Market Research
Due Diligence
Infectious Diseases
Fda
Analysis
Interests:
Economic Empowerment
Civil Rights and Social Action
Education
Science and Technology
Health
Eben Tessari Photo 2

Eben Tessari Boston, MA

View page
Work:
Series C Private Placement

Sep 2014 to Sep 2014
Licensed pre-clinical compounds to VC
Zalicus, Inc

Mar 2013 to Nov 2013
Associate Director, Business & Corporate Development
Vertex Pharmaceuticals

2010 to 2013
Sr. Manager, New Product Strategy & Decision Analytics
EPIX Pharmaceuticals

2007 to 2009
Associate, Corporate & Business Development
Education:
Suffolk University
2009 to 2014
MBA in finance and IP law
Boston University
2004 to 2007
MS in Biomedical Engineering
Northeastern University
2000 to 2004
BS in Neuroscience

Business Records

Name / Title
Company / Classification
Phones & Addresses
Eben Null Tessari
Business Development Director
EPIX PHARMACEUTICALS, INC
Discovers and Develops Pharmaceutical Products · Pharmaceutical Preparations · Commercial Research
4 Maguire Rd, Lexington, MA 02421
167 Worcester St, Wellesley, MA 02481
(781) 761-7600

Publications

Us Patents

Treatment Of Cancers With Gm-Csf Antagonists

View page
US Patent:
20220184179, Jun 16, 2022
Filed:
Oct 26, 2021
Appl. No.:
17/511183
Inventors:
- Hamilton, BM
Eben Tessari - Lexington MA, US
Luis Carvajal - Lexington MA, US
Annalisa D'andrea - Lexington MA, US
International Classification:
A61K 38/17
C07K 16/28
A61K 45/06
A61P 35/00
Abstract:
The present invention provides, among other things, a method of treating cancer comprising administering a GM-CSF antagonist to the patient in need of treatment, wherein the administration of the GM-CSF antagonist improves, stabilizes or reduces one or more symptoms of the cancer in the patient. The present invention also provides, among other things, a method of inhibiting progression of cancer in a patient suffering from cancer with one or more mutations in KRAS, NRAS and/or JAK2 comprising administering a GM-CSF antagonist to the patient.

Treatment Of Cytokine Release Syndrome With Gm-Csf Antagonists

View page
US Patent:
20210284744, Sep 16, 2021
Filed:
Mar 15, 2021
Appl. No.:
17/201698
Inventors:
- Hamilton, BM
John Paolini - Lexington MA, US
Eben Tessari - Lexington MA, US
International Classification:
C07K 16/28
A61P 31/14
Abstract:
The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.

Treatment Of Cytokine Release Syndrome With Gm-Csf Antagonists

View page
US Patent:
20210284745, Sep 16, 2021
Filed:
May 19, 2021
Appl. No.:
17/324931
Inventors:
- Hamilton, BM
John Paolini - Lexington MA, US
Eben Tessari - Lexington MA, US
International Classification:
C07K 16/28
A61K 31/685
A61K 31/573
A61P 31/14
Abstract:
The present invention provides, among other things, a method of treating a subject with infection-induced hyperinflammation comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of hyperinflammation. The present invention also provides, among other things, a method of inhibiting or reducing cytokine release syndrome (CRS) or acute respiratory distress syndrome (ARDS) in a subject comprising administering to the subject a granulocyte-macrophage colony-stimulating factor (GM-CSF) antagonist at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more symptoms of CRS or ARDS.

Treatment Of Inflammatory Conditions By Delivery Of Interleukin-1 Receptor Antagonist Fusion Protein

View page
US Patent:
20190151417, May 23, 2019
Filed:
Sep 26, 2018
Appl. No.:
16/143391
Inventors:
- Tarrytown NY, US
Eben Tessari - Lexington MA, US
International Classification:
A61K 38/20
A61P 9/00
A61K 47/68
Abstract:
The present invention provides, among other things, methods of treating post-cardiac injury syndrome (PCIS) or pericarditis, comprising a step of administering to a subject in need of treatment an interleukin-1 receptor-Fc fusion protein at a therapeutically effective dose and an administration interval for a treatment period sufficient to improve, stabilize or reduce one or more signs and symptoms of pericarditis relative to a control.
Control profile
Eben P Tessari from Boston, MA, age ~43 Get Report